Cardiotoxicity Of Anti-Tumor Treatment Of Anti-Tumor Treatment Of Breast Cancer: Challenges And Prospects

Abstract

The article discusses the problem of cardiotoxicity that occurs during the use of antitumor treatment and its impact on the cardiovascular system. Various anticancer drugs, including trastuzumab, can cause myocardial dysfunction and heart failure, leading to increased heart morbidity and mortality in patients. Existing diagnostic methods are not always able to identify early signs of myocardial damage, so the introduction of modern technologies is required for the early assessment of myocardial dysfunction and the development of preventive measures. The article highlights the importance of collaboration between specialists caring for cancer patients to prevent and manage cardiotoxicity. Future research should focus on better understanding the mechanisms of cardiotoxicity, developing new diagnostic and prevention methods, and conducting clinical trials to identify effective strategies for the prevention and management of cardiotoxicity. Exchange of experience and training between specialists from different fields of medicine also play an important role in achieving the best treatment outcomes for patients with cancer.